Mesane Ürotelyal Karsinom Varyantları

Lopez-Beltran A, Henriques V, Montironi R et al. Variants and new entities of bladder cancer. Histopathology. 2019 Jan;74(1):77-96. doi: 10.1111/his.13752. PMID: 30565299.

Lobo N, Shariat SF, Guo CC et al. What Is the Significance of Variant Histology in Urothelial Carcinoma? Eur Urol Focus. 2020 Jul 15;6(4):653-663. doi: 10.1016/j.euf.2019.09.003. Epub 2019 Sep 15. PMID: 31530497

Moch H, Humphrey PA, Ulbright TM et al. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer; 2016

Aron M. Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes. Curr Urol Rep. 2019 Nov 28;20(12):80. doi: 10.1007/s11934-019-0949-6. PMID: 31781939

Scosyrev E, Ely BW, Messing EM et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 2011 Sep;108(5):693-9. doi: 10.1111/j.1464-410X.2010.09900.x. Epub 2010 Nov 24. PMID: 21105991; PMCID: PMC3117124.

Mitra AP, Bartsch CC, Bartsch G Jr et al. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol. 2014 Feb;32(2):117-27. doi: 10.1016/j.urolonc.2012.08.017. Epub 2013 Mar 7. PMID: 23477878.

Kulkarni GS, Hermanns T, Wei Y et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14. PMID: 28410011

Nagumo Y, Kojima T, Shiga M et al. A single-institute experience of trimodal bladder-preserving therapy for histologic variants of urothelial carcinoma. Int J Clin Oncol. 2020 Feb;25(2):354-361. doi: 10.1007/s10147-019-01553-4. Epub 2019 Oct 8. PMID: 31595343.

Moschini M, D'Andrea D, Korn S, et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol. 14(11):651-668. doi:10.1038/nrurol.2017.125

Lopez-Beltran A, Requena MJ, Alvarez-Kindelan J, et al. Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. J Clin Pathol. 2007;60(3):332-335. doi:10.1136/jcp.2006.038802

Liu Y, Bui MM, Xu B. Urothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis. Cancer Control. 2017;24(1):78-82. doi:10.1177/107327481702400113

Li G, Hu J, Niu Y. Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy. Oncotarget, 9(1), 217 DOI: 10.18632/ 18563. 2018

Gofrit ON, Yutkin V, Shapiro A, et al. The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer. Front Oncol. 2016;6:43. Published 2016 Mar 15. doi:10.3389/fonc.2016.00043

Li G, Yu J, Song H, et al. Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival. BMC Cancer. 2017;17(1):530. Published 2017 Aug 8. doi:10.1186/s12885-017-3520-1

Gulmann C, Paner GP, Parakh RS, et al. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum Pathol. 2013;44(2):164-172. doi:10.1016/j.humpath.2012.05.018

Paner GP, Annaiah C, Gulmann C, et al. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum Pathol. 2014;45(7):1473-1482. doi:10.1016/j.humpath.2014.02.024

Alexander RE, Hu Y, Kum JB, et al. p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. Mod Pathol. 2012;25(11):1526-1533. doi:10.1038/modpathol.2012.103

Vail E, Zheng X, Zhou M, et al. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. Ann Diagn Pathol. 2015;19(5):301-305. doi:10.1016/j.anndiagpath.2015.06.007

Yang Z, Epstein JI. Urothelial Carcinoma In Situ of the Bladder With Glandular Differentiation: Report of 92 Cases. Am J Surg Pathol. 2018;42(7):971-976. doi:10.1097/PAS.0000000000001073

Mitra AP, Bartsch CC, Bartsch G Jr, et al. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol. 2014;32(2):117-127.

Kim SP, Frank I, Cheville JC, et al. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol. 2012;188(2):405-409. doi:10.1016/j.juro.2012.04.020

Lee YJ, Moon KC, Jeong CW, et al. Impact of squamous and glandular differentiation on oncologic outcomes in upper and lower tract urothelial carcinoma. PLoS One. 2014;9(9):e107027. Published 2014 Sep 5. doi:10.1371/journal.pone.0107027

Zhao G, Wang C, Tang Y, et al. Glandular differentiation in pT1 urothelial carcinoma of bladder predicts poor prognosis. Sci Rep. 2019;9(1):5323. Published 2019 Mar 29. doi:10.1038/s41598-019-41844-4

Douglas J, Sharp A, Chau C, et al. Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract. Br J Cancer. 2014;110(7):1759-1766. doi:10.1038/bjc.2014.89

Monn MF, Kaimakliotis HZ, Pedrosa JA, et al. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol Oncol. 2015;33(1):18.e15-18.e20. doi:10.1016/j.urolonc.2014.10.001

Kinoshita Y, Takasu K, Yuri T, et al. Cytological findings in urothelial carcinoma of the bladder with trophoblastic differentiation. Cytopathology. 2013;24(6):405-408. doi:10.1111/j.1365-2303.2012.00993.x

Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009;22 Suppl 2:S96-S118. doi:10.1038/modpathol.2009.26

Weyerer V, Weisser R, Moskalev EA, et al. Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. Histopathology. 2019;75(6):865-875. doi:10.1111/his.13958

Legesse T, Matoso A, Epstein JI. PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall. Hum Pathol. 2019;94:11-15. doi:10.1016/j.humpath.2019.09.012

Hacıhasanoğlu E, Behzatoğlu K. Large nested urothelial carcinoma: A clinicopathological study of 22 cases on transurethral resection materials. Ann Diagn Pathol. 2019;42:7-11. doi:10.1016/j.anndiagpath.2019.06.005

Brimo F, Dauphin-Pierre S, Aprikian A, et al. Inverted urothelial carcinoma: a series of 12 cases with a wide morphologic spectrum overlapping with the large nested variant. Hum Pathol. 2015;46(10):1506-1513. doi:10.1016/j.humpath.2015.06.010

Allory Y, Beukers W, Sagrera A et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014 Feb;65(2):360-6. doi: 10.1016/j.eururo.2013.08.052. Epub 2013 Sep 7. PMID: 24018021

Warrick JI, Kaag M, Raman JD, et al. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma. Virchows Arch. 2017;471(3):337-345. doi:10.1007/s00428-017-2190-3

Wasco MJ, Daignault S, Bradley D, et al. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases. Hum Pathol. 2010;41(2):163-171. doi:10.1016/j.humpath.2009.07.015

Compérat E, McKenney JK, Hartmann A, et al. Large nested variant of urothelial carcinoma: a clinicopathological study of 36 cases. Histopathology. 2017;71(5):703-710. doi:10.1111/his.13280

Beltran AL, Cheng L, Montironi R, et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch. 2014;465(2):199-205. doi:10.1007/s00428-014-1601-y

Mally AD, Tin AL, Lee JK, et al. Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder [published online ahead of print, 2017 Jul 14]. Clin Genitourin Cancer. 2017;S1558-7673(17)30199-4. doi:10.1016/j.clgc.2017.07.002

Linder BJ, Frank I, Cheville JC, et al. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol. 2013;189(5):1670-1675. doi:10.1016/j.juro.2012.11.006

Lopez Beltran A, Montironi R, Cheng L. Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. Histopathology. 2014;64(6):872-879. doi:10.1111/his.12345

Young RH, Zukerberg LR. Microcystic transitional cell carcinomas of the urinary bladder. A report of four cases. Am J Clin Pathol. 1991;96(5):635-639. doi:10.1093/ajcp/96.5.635

Zhong M, Tian W, Zhuge J, et al. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol. 2015;39(1):127-131. doi:10.1097/PAS.0000000000000305

Compérat E, Roupret M, Yaxley J, et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology. 2010;42(7):650-654. doi:10.3109/00313025.2010.522173

Sangoi AR, Beck AH, Amin MB, et al. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol. 2010;34(9):1367-1376. doi:10.1097/PAS.0b013e3181ec86b3

Nassar H, Pansare V, Zhang H, et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol. 2004;17(9):1045-1050. doi:10.1038/modpathol.3800166

Guo CC, Dadhania V, Zhang L, et al. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016;70(4):611-620. doi:10.1016/j.eururo.2016.02.056

Watts KE, Hansel DE. Emerging concepts in micropapillary urothelial carcinoma. Adv Anat Pathol. 2010;17(3):182-186. doi:10.1097/PAP.0b013e3181d97851

Lopez-Beltran A, Montironi R, Blanca A, et al. Invasive micropapillary urothelial carcinoma of the bladder. Hum Pathol. 2010;41(8):1159-1164. doi:10.1016/j.humpath.2009.11.018

Willis DL, Fernandez MI, Dickstein RJ, et al. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015;193(4):1129-1134. doi:10.1016/j.juro.2014.09.092

Schneider SA, Sukov WR, Frank I, et al. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 2014;27(5):758-764. doi:10.1038/modpathol.2013.201

Giannico GA, Gown AM, Epstein JI, et al. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract. Hum Pathol. 2017;67:152-159. doi:10.1016/j.humpath.2017.07.002

Zinnall U, Weyerer V, Compérat E, et al. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Hum Pathol. 2018;80:55-64. doi:10.1016/j.humpath.2018.05.022

Figueroa JD, Ye Y, Siddiq A, et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014;23(5):1387-1398. doi:10.1093/hmg/ddt519

Nguyen D, Taheri D, Springer S, et al. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Arch. 2016;469(4):427-434. doi:10.1007/s00428-016-2001-2

Amin MB, Ro JY, Lee KM, et al. Lymphoepithelioma-like carcinoma of the urinary bladder. Am J Surg Pathol. 1994;18(5):466-473. doi:10.1097/00000478-199405000-00005

Lopez-Beltrán A, Luque RJ, Vicioso L, et al. Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. Virchows Arch. 2001;438(6):552-557. doi:10.1007/s004280000378

Rodríguez-Cabello MA, Méndez-Rubio S, Sanz-Miguelañez JL, et al. Lymphoepithelioma-Like Bladder Carcinoma: A Diagnostic and Therapeutic Challenge. Contribution Using a New Case and Review of the Literature. Clin Genitourin Cancer. 2017;15(3):e507-e515. doi:10.1016/j.clgc.2016.12.023

Tamas EF, Nielsen ME, Schoenberg MP, et al. Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol. 2007;20(8):828-834. doi:10.1038/modpathol.3800823

Yoshino T, Ohara S, Moriyama H. Lymphoepithelioma-like carcinoma of the urinary bladder: a case report and review of the literature. BMC Res Notes. 2014;7:779. Published 2014 Nov 4. doi:10.1186/1756-0500-7-779

Yang AW, Pooli A, Lele SM, et al. Lymphoepithelioma-like, a variant of urothelial carcinoma of the urinary bladder: a case report and systematic review for optimal treatment modality for disease-free survival. BMC Urol. 2017;17(1):34. Published 2017 Apr 27. doi:10.1186/s12894-017-0224-4

Lopez-Beltran A, Requena MJ, Montironi R, et al. Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol. 2009;40(7):1023-1028. doi:10.1016/j.humpath.2009.01.001

Ricardo-Gonzalez RR, Nguyen M, Gokden N, et al. Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread. J Urol. 2012;187(3):852-855. doi:10.1016/j.juro.2011.10.145

Kaimakliotis HZ, Monn MF, Cary KC, et al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?. Urol Oncol. 2014;32(6):833-838. doi:10.1016/j.urolonc.2014.03.008

Fox MD, Xiao L, Zhang M, et al. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017;147(5):500-506. doi:10.1093/ajcp/aqx029

Al-Ahmadie HA, Iyer G, Lee BH, et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet. 2016;48(4):356-358. doi:10.1038/ng.3503

Wang X, Lopez-Beltran A, Osunkoya AO, et al. TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. Future Oncol. 2017;13(8):705-714. doi:10.2217/fon-2016-0414

Dayyani F, Czerniak BA, Sircar K, et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013;189(5):1656-1661. doi:10.1016/j.juro.2012.11.084

Cheng L, Zhang S, Alexander R, et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol. 2011;35(5):e34-e46. doi:10.1097/PAS.0b013e3182159dec

Sanfrancesco J, McKenney JK, Leivo MZ, et al. Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition. Arch Pathol Lab Med. 2016;140(6):543-551. doi:10.5858/arpa.2015-0085-OA

Lopez-Beltran A, Pacelli A, Rothenberg HJ, et al. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol. 1998;159(5):1497-1503. doi:10.1097/00005392-199805000-00023

Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017;123(22):4346-4355. doi:10.1002/cncr.30907

Berg S, D'Andrea D, Vetterlein MW, et al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. Cancer. 2019;125(9):1449-1458. doi:10.1002/cncr.31952

Samaratunga H, Delahunt B, Egevad L, et al. Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de-differentiation. Histopathology. 2016;68(4):533-540. doi:10.1111/his.12785

Lopez-Beltran A, Blanca A, Montironi R, et al. Pleomorphic giant cell carcinoma of the urinary bladder. Hum Pathol. 2009;40(10):1461-1466. doi:10.1016/j.humpath.2009.02.016

Solomon JP, Lowenthal BM, Kader AK, et al. Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?. Urology. 2017;102:7-16. doi:10.1016/j.urology.2016.10.014

Samaratunga H, Delahunt B. Recently described and unusual variants of urothelial carcinoma of the urinary bladder. Pathology. 2012;44(5):407-418. doi:10.1097/PAT.0b013e3283560172

Priore SF, Schwartz LE, Epstein JI. An expanded immunohistochemical profile of osteoclast-rich undifferentiated carcinoma of the urinary tract. Mod Pathol. 2018;31(6):984-988. doi:10.1038/s41379-018-0012-z

Lopez-Beltran A, Amin MB, Oliveira PS, et al. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. Am J Surg Pathol. 2010;34(3):371-376. doi:10.1097/PAS.0b013e3181cd385b

Kojima Y, Takasawa A, Murata M, et al. A case of urothelial carcinoma, lipid cell variant. Pathol Int. 2013;63(3):183-187. doi:10.1111/pin.12027

Mihai I, Taban S, Cumpanas A, et al. Clear cell urothelial carcinoma of the urinary bladder - a rare pathological entity. A case report and a systematic review of the literature. Bosn J Basic Med Sci. 2019;19(4):400-403. Published 2019 Nov 8. doi:10.17305/bjbms.2019.4182

Knez VM, Barrow W, Lucia MS, et al. Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature. J Med Case Rep. 2014;8:275. Published 2014 Aug 14. doi:10.1186/1752-1947-8-275

Yamashita R, Yamaguchi R, Yuen K, et al. Urothelial carcinoma (clear cell variant) diagnosed with useful immunohistochemistry stain. Int J Urol. 2006;13(11):1448-1450. doi:10.1111/j.1442-2042.2006.01569.x

Dadhania V, Czerniak B, Guo CC. Adenocarcinoma of the urinary bladder. Am J Clin Exp Urol. 2015;3(2):51-63. Published 2015 Aug 8.

Mai KT, Bateman J, Djordjevic B, et al. Clear Cell Urothelial Carcinoma. Int J Surg Pathol. 2017;25(1):18-25. doi:10.1177/1066896916660195